Barrington Research Predicts Higher Earnings for Surmodics

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Investment analysts at Barrington Research raised their FY2025 earnings per share estimates for shares of Surmodics in a research report issued to clients and investors on Thursday, November 7th. Barrington Research analyst M. Petusky now anticipates that the company will post earnings per share of $0.21 for the year, up from their previous forecast of $0.19. The consensus estimate for Surmodics' current full-year earnings is $0.16 per share. Barrington Research also issued estimates for Surmodics' Q4 2025 earnings at $0.17 EPS.

A number of other brokerages have also recently issued reports on SRDX. StockNews.com assumed coverage on shares of Surmodics in a report on Thursday. They set a "hold" rating for the company. Needham & Company LLC reissued a "hold" rating on shares of Surmodics in a report on Thursday. Five investment analysts have rated the stock with a hold rating, According to data from MarketBeat, Surmodics presently has an average rating of "Hold" and an average price target of $50.00.

Surmodics Trading Up 0.2 %

Shares of Surmodics stock traded up $0.07 during trading on Friday, hitting $38.47. 20,743 shares of the company were exchanged, compared to its average volume of 230,376. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.98 and a quick ratio of 3.22. The firm has a market capitalization of $548.97 million, a P/E ratio of -47.41 and a beta of 1.20. The firm's fifty day moving average price is $38.60 and its 200 day moving average price is $38.60. Surmodics has a 1-year low of $25.17 and a 1-year high of $42.44.

Hedge Funds Weigh In On Surmodics

A number of large investors have recently added to or reduced their stakes in the company. Phocas Financial Corp. bought a new position in shares of Surmodics during the third quarter worth about $3,430,000. Quest Partners LLC grew its stake in Surmodics by 107,100.0% in the third quarter. Quest Partners LLC now owns 1,072 shares of the company's stock valued at $42,000 after purchasing an additional 1,071 shares in the last quarter. Wolverine Asset Management LLC raised its stake in shares of Surmodics by 6.9% during the 3rd quarter. Wolverine Asset Management LLC now owns 27,766 shares of the company's stock worth $1,077,000 after purchasing an additional 1,800 shares in the last quarter. Principal Financial Group Inc. acquired a new position in Surmodics during the third quarter worth $1,190,000. Finally, Olympiad Research LP bought a new stake in Surmodics during the third quarter worth $1,884,000. Institutional investors own 96.63% of the company's stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).